ORAMED PHARMACEUTICALS INC.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year ended December 31, · Year ended December 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| REVENUES | $2,000 | $ | - |
| COST OF REVENUE | (1,987) | - | |
| GROSS PROFIT | 13 | - | |
| RESEARCH AND DEVELOPMENT EXPENSES | (6,381) | (6,324) | |
| GENERAL AND ADMINISTRATIVE EXPENSES | (8,720) | (6,457) | |
| OPERATING LOSS | (15,088) | (12,781) | |
| OTHER INCOME, NET | 958 | - | |
| INTEREST EXPENSES (note 12) | - | (853) | |
| FINANCIAL INCOME (LOSS), NET (note 17) | 89,454 | (2,286) | |
| INCOME (LOSS) BEFORE TAX EXPENSES | 75,324 | (15,920) | |
| TAX EXPENSES | (11,308) | (3,183) | |
| NET INCOME (LOSS) | $64,016 | $(19,103) | |
| NET INCOME (LOSS) ATTRIBUTABLE TO: | |||
| NON-CONTROLLING INTERESTS | (34) | (43) | |
| COMPANY’S STOCKHOLDERS | $64,050 | $(19,060) | |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | $1.53 | $(0.48) | |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | $1.50 | $(0.48) | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | 41,402,997 | 40,850,446 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | 42,418,644 | 40,850,446 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.